Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Xeris Pharmaceuticals Inc (XERS)

Xeris Pharmaceuticals Inc (XERS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Xeris Pharmaceuticals Appoints Mark Thierer to Board of Directors

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug...

XERS : 7.92 (-7.58%)
Xeris Pharmaceuticals Begins Dosing Patients in a Phase 2 Clinical Trial Evaluating Its Novel Fixed-Ratio Co-Formulation of Pramlintide-Insulin for Diabetes

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug...

XERS : 7.92 (-7.58%)
Xeris Pharmaceuticals Announces Expanded $85 Million Debt Facility With Oxford Finance and Silicon Valley Bank

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug...

XERS : 7.92 (-7.58%)
Xeris Pharmaceuticals Receives U.S. FDA Approval for GVOKE(TM) (glucagon), the First Ready-to-use Stable Liquid Glucagon for Severe Hypoglycemia

--GVOKE is the first premixed, prefilled, premeasured liquid glucagon offering ease of use for pediatric and adult patients with diabetes ages 2 years and above or caregivers to rapidly treat severe hypoglycemic...

XERS : 7.92 (-7.58%)
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations,...

XERS : 7.92 (-7.58%)
Xeris Pharmaceuticals to Present at Two September Healthcare Conferences

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug...

WFC : 50.62 (+0.32%)
XERS : 7.92 (-7.58%)
Xeris Pharmaceuticals, Inc. (XERS) Reports Q2 Loss, Tops Revenue Estimates

Xeris Pharmaceuticals, Inc. (XERS) delivered earnings and revenue surprises of -31.96% and 57.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?...

XERS : 7.92 (-7.58%)
Xeris Pharmaceuticals Announces Second Quarter 2019 Financial Results and Highlights

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug...

XERS : 7.92 (-7.58%)
Xeris Pharmaceuticals, Inc. (XERS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Xeris Pharmaceuticals, Inc. (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

XERS : 7.92 (-7.58%)
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations,...

XERS : 7.92 (-7.58%)
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations,...

XERS : 7.92 (-7.58%)
Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Developmental Ready-to-use Glucagon in Patients at Risk From Hypoglycemia Following Bariatric Surgery

Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations,...

XERS : 7.92 (-7.58%)
Xeris Pharmaceuticals Receives Notification of PDUFA Date Extension for Gvoke(TM)

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations,...

XERS : 7.92 (-7.58%)
Xeris Pharmaceuticals Announces First Quarter 2019 Financial Results and Highlights Its Pipeline

Continuing to execute commercial build and launch readiness for Gvoke HypoPen(TM) and Gvoke PFS(TM)

XERS : 7.92 (-7.58%)
Xeris Pharmaceuticals Announces Results From a Phase 1 Study of Its Novel Formulation of Diazepam

Favorable pharmacokinetic, safety, and tolerability results support continued development of Xeris' diazepam

XERS : 7.92 (-7.58%)
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations,...

XERS : 7.92 (-7.58%)
Xeris Pharmaceuticals Presents New Clinical and Economic Impact Data on Its Developmental Ready-to-Use Glucagon

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible...

XERS : 7.92 (-7.58%)
Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Ready-to-Use Glucagon to Address Exercise-Induced Hypoglycemia

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible...

XERS : 7.92 (-7.58%)
Xeris Pharmaceuticals Announces Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline Progress

Continuing to execute commercial build and launch readiness for Gvoke HypoPen(TM)

XERS : 7.92 (-7.58%)
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations,...

XERS : 7.92 (-7.58%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI -2.05 , AIZ -1.32 , SBAC -0.85 , SO -0.15 , WELL -0.29
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar